Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

Layla M Saleh, MD, Weixin Wang, PhD, Sarah E. M. Herman, PhD, Mohammed Farooqui, DO, Clare Sun, MD, Emily Barber, B.S., Meghan Corrigan-Cummins, B.S., Nakhle Saba, MD, Hasan Awad, MD, PhD, Adrian Wiestner, MD PhD, Katherine R. Calvo, MD, PhD

Blood (2015) 126 (23): 487.

https://doi.org/10.1182/blood.V126.23.487.487

Published: 2015

Journal Articles

High Sensitivity Testing Shows Multiclonal Mutations in Patients with CLL Treated with BTK Inhibitor and Lack of Mutations in Ibrutinib-Naive Patients

Adam Albitar, Wanlong Ma, BS, Ivan De Dios, Jeffrey Estrella, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD, Maher Albitar

Blood (2015) 126 (23): 716.

https://doi.org/10.1182/blood.V126.23.716.716

Published: 2015

Journal Articles

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Inhye Ahn, MD, Mohammed Farooqui, DO, Yuh Shan Lee, Gerald Marti, Susan Soto, RN, Xin Tian, PhD, Maryalice Stetler-Stevenson, Constance M. Yuan, MD PhD, Irina Maric, MD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 1750.

https://doi.org/10.1182/blood.V126.23.1750.1750

Published: 2015

Journal Articles

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Amanda Bray, RN, Xin Tian, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2933.

https://doi.org/10.1182/blood.V126.23.2933.2933

Published: 2015

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 1936.

https://doi.org/10.1182/blood.V124.21.1936.1936

Published: 2014

Journal Articles

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Georg Aue, MD, Mohammed Farooqui, DO, Jade Jones, Janet Valdez, PA, Sabrina E. Martyr, MD, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 4182.

https://doi.org/10.1182/blood.V122.21.4182.4182

Published: 2013

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

Journal Articles

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Carsten U Niemann, MD, PhD, Angelique Biancotto, PhD, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, J. Philip McCoy, Jr., Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 2856.

https://doi.org/10.1182/blood.V122.21.2856.2856

Published: 2013

Journal Articles

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Sarah E. M. Herman, PhD, Jade Jones, Rashida Z. Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 604.

https://doi.org/10.1182/blood.V122.21.604.604

Published: 2013

Journal Articles

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Mohammed Farooqui, DO, Georg Aue, MD, Janet Valdez, PA, Sabrina Martyr, MD, Jade Jones, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Diane C Arthur, M.D., Francine Thomas, B.S., Xin Tian, PhD, Delong Liu, PhD, Irina Maric, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 673.

https://doi.org/10.1182/blood.V122.21.673.673

Published: 2013

Journal Articles

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Rashida Z Mustafa, BS, Sarah E. M. Herman, PhD, Jade Jones, Jennifer Gyamfi, MS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 674.

https://doi.org/10.1182/blood.V122.21.674.674

Published: 2013

Journal Articles

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Mark Roschewski, MD, Mohammed Farooqui, DO, Georg Aue, MD, Clifton C. Mo, MD, Janet Valdez, PA, Susan Soto, RN, Patricia Perez-Galan, PhD, Francois Wilhelm, MD, PhD., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1803.

https://doi.org/10.1182/blood.V120.21.1803.1803

Published: 2012

Journal Articles

In Vivo Effects of Ibrutinib On BCR Signaling, Tumor Cell Activation and Proliferation in Blood and Tissue-Resident Cells of Chronic Lymphocytic Leukemia Patients

Sarah E. M. Herman, PhD, Mohammed Farooqui, DO, Rahel Bezabhie, Georg Aue, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 185.

https://doi.org/10.1182/blood.V120.21.185.185

Published: 2012

Journal Articles

Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation

Mohammed Farooqui, DO, Jay Nelson Lozier, Janet Valdez, PA, Nakhle Saba, MD, Ajunae Wells, Susan Soto, RN, Delong Liu, Ph.D., Georg Aue, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1789.

https://doi.org/10.1182/blood.V120.21.1789.1789

Published: 2012

Journal Articles

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Nakhle Saba, MD, Min Shen, PhD, Mondana Ghias, Mohammed Farooqui, DO, Christopher Austin, MD, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 865.

https://doi.org/10.1182/blood.V120.21.865.865

Published: 2012

Journal Articles

Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.

Mohammed Farooqui, DO, Georg Aue, MD, Janet Valdez, PA, Nakhle Saba, MD, Sarah E. M. Herman, PhD, Andrew Lipsky, MS IV, Leodayan Bojanowski, DNP, CIP, RN, Ajunae Wells, Susan Soto, RN, Delong Liu, Ph.D., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 2899.

https://doi.org/10.1182/blood.V120.21.2899.2899

Published: 2012

Journal Articles

Significance of, and Difficulty in Diagnosing, Erythropoietin Deficiency in Sickle Cell Anemia

Santosh L Saraf, MD, Seema Sidhwani, DO, Mohammed Farooqui, DO, Giovanni Infusino, MD, Lani Krauz, RN, Michael Gowhari, MD, Stephen Vara, MD, Louise Dorn, RN, MS, Joseph Desimone, PhD, Robert Molokie, MD, Yogen Saunthararajah, MD

Blood (2008) 112 (11): 2479.

https://doi.org/10.1182/blood.V112.11.2479.2479

Published: 2008

NARROW

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

High Sensitivity Testing Shows Multiclonal Mutations in Patients with CLL Treated with BTK Inhibitor and Lack of Mutations in Ibrutinib-Naive Patients

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

In Vivo Effects of Ibrutinib On BCR Signaling, Tumor Cell Activation and Proliferation in Blood and Tissue-Resident Cells of Chronic Lymphocytic Leukemia Patients

Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.

Significance of, and Difficulty in Diagnosing, Erythropoietin Deficiency in Sickle Cell Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only